Skip to main content
SpringerLink
Log in

Circulating Tumor Cells and Tumor Dormancy

  • Chapter
  • First Online:
Circulating Tumor Cells

Part of the book series: Current Cancer Research ((CUCR))

  • 1612 Accesses

Abstract

Metastatic cancer can recur months or even years after apparently successful treatment of the primary tumor. While the exact mechanisms leading to cancer recurrence remain poorly understood, failure to completely eliminate dormant micrometastases and solitary metastatic cells is believed to be a major contributor. Thus, while not of initial clinical concern, metastatic dormancy is still a significant clinical problem. The emerging use of circulating tumor cells (CTCs) as prognostic and predictive biomarkers for monitoring and understanding metastatic disease may provide an opportunity to address this challenge. In this chapter we discuss the current knowledge relating to CTCs and tumor dormancy, and the relationship between the two with regard to metastasis biology and treatment. We also consider the clinical impact of monitoring for CTCs in the absence of symptomatic tumor recurrence and what is needed for such an approach to providing “actionable” information that will improve patient outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8):563–572

    Article  CAS  PubMed  Google Scholar 

  2. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456

    Article  CAS  PubMed  Google Scholar 

  3. Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8(5):329–340

    Article  CAS  PubMed  Google Scholar 

  4. Miller MC, Doyle GV, Terstappen LW (2010) Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010:617421

    Article  PubMed Central  PubMed  Google Scholar 

  5. Ashworth TR (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 14:146–149

    Google Scholar 

  6. Allan AL, Keeney M (2010) Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol 2010:426218

    Article  PubMed Central  PubMed  Google Scholar 

  7. Tibbe AG, Miller MC, Terstappen LW (2007) Statistical considerations for enumeration of circulating tumor cells. Cytometry A 71(3):154–162

    Article  PubMed  Google Scholar 

  8. Sleijfer S, Gratama JW, Sieuwerts AM, Kraan J, Martens JW, Foekens JA (2007) Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer 43(18):2645–2650

    Article  CAS  PubMed  Google Scholar 

  9. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee J, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ (2012) Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 10:138

    Article  PubMed Central  PubMed  Google Scholar 

  10. Lowes LE, Goodale D, Keeney M, Allan AL (2011) Image cytometry analysis of circulating tumor cells. Methods Cell Biol 102:261–290

    Article  CAS  PubMed  Google Scholar 

  11. Alix-Panabieres C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59(1):110–118

    Article  CAS  PubMed  Google Scholar 

  12. Yu M, Stott S, Toner M, Maheswaran S, Haber DA (2011) Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 192(3):373–382

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Pantel K, Alix-Panabieres C (2013) Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res 73(21):6384–6388

    Article  CAS  PubMed  Google Scholar 

  14. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791

    Article  CAS  PubMed  Google Scholar 

  15. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302–6309

    Article  PubMed  CAS  Google Scholar 

  16. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26(19):3213–3221

    Article  PubMed  Google Scholar 

  17. Neki K, Kawahara H, Watanabe K, Toyama Y, Akiba T, Yanaga K (2013) Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer. Anticancer Res 33(4):1769–1772

    CAS  PubMed  Google Scholar 

  18. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12(14 Pt 1):4218–4224

    Article  CAS  PubMed  Google Scholar 

  19. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF (2006) Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res 12(21):6403–6409

    Google Scholar 

  20. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359(4):366–377

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P (2012) High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol 9(1):016004

    Article  PubMed Central  PubMed  Google Scholar 

  22. Hiltermann TJ, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJ, Schouwink JH, Wijnands WJ, Kerner GS, Kruyt FA, Tissing H, Tibbe AG, Terstappen LW, Groen HJ (2012) Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol 23(11):2937–2942

    Article  CAS  PubMed  Google Scholar 

  23. Huang J, Wang K, Xu J, Huang J, Zhang T (2013) Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PLoS One 8(11):e78070

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Han L, Chen W, Zhao Q (2014) Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Tumour Biol 35(3):2473–80

    Article  CAS  PubMed  Google Scholar 

  25. Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Buchler MW, Koch M, Weitz J (2010) Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 138(5):1714–1726

    Article  PubMed  Google Scholar 

  26. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, Liu J, Pantel K (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18(20):5701–5710

    Article  PubMed  Google Scholar 

  27. Wang FB, Yang XQ, Yang S, Wang BC, Feng MH, Tu JC (2011) A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients--a meta-analysis. Asian Pac J Cancer Prev 12(10):2629–2635

    Google Scholar 

  28. AJCC (2010) Breast. In: Edge SB, Byrd DR, Compton CC et al (eds) AJCC cancer staging manual, 7th edn. Springer, New York, NY, pp 347–376

    Google Scholar 

  29. King JD, Casavant BP, Lang JM (2014) Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements. Lab Chip 14(1):24–31

    Article  CAS  PubMed  Google Scholar 

  30. Plaks V, Koopman CD, Werb Z (2013) Cancer. Circulating tumor cells. Science 341(6151):1186–1188

    Article  CAS  PubMed  Google Scholar 

  31. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P (2012) Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol 9(1):016001

    Article  PubMed Central  PubMed  Google Scholar 

  32. Kuhn P, Bethel K (2012) A fluid biopsy as investigating technology for the fluid phase of solid tumors. Phys Biol 9(1):010301

    Article  PubMed Central  PubMed  Google Scholar 

  33. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P (2012) Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 9(1):016003

    Article  PubMed Central  PubMed  Google Scholar 

  34. Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, Marrinucci D, Sandhu A, Perricone A, Thistlethwaite P, Bethel K, Nieva J, Heuvel M, Kuhn P (2012) Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol 9(1):016005

    Article  PubMed Central  PubMed  Google Scholar 

  35. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA (2012) Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2(11):995–1003

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235–1239

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M (2013) Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5(179):179ra147

    Article  CAS  Google Scholar 

  38. Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ (2009) The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 4(3):281–283

    Article  PubMed Central  PubMed  Google Scholar 

  39. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP Jr, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107(43):18392–18397

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S (2010) Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2(25):25ra23

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  41. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580–584

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA (2012) RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487(7408):510–513

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Sleijfer S, Foekens JA (2011) Medical oncology: clinical value of circulating tumor cells in breast cancer. Nat Rev Clin Oncol 8(12):696–698

    Article  PubMed  Google Scholar 

  44. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bauerle T, Wallwiener M, Holland-Letz T, Hofner T, Sprick M, Scharpff M, Marme F, Sinn HP, Pantel K, Weichert W, Trumpp A (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544

    Article  CAS  PubMed  Google Scholar 

  45. Cristofanilli M, Mendelsohn J (2006) Circulating tumor cells in breast cancer: advanced tools for “tailored” therapy? Proc Natl Acad Sci U S A 103(46):17073–17074

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Goodale D, Phay C, Postenka CO, Keeney M, Allan AL (2009) Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry. Cytometry A 75(4):344–355

    Article  PubMed  CAS  Google Scholar 

  47. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101(25):9393–9398

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Lohberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K (2010) HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 124(2):403–412

    Article  CAS  PubMed  Google Scholar 

  49. Kim P, Liu X, Lee T, Liu L, Barham R, Kirkland R, Leesman G, Kuller A, Ybarrondo B, Ng SC, Singh S (2011) Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteome Sci 9(1):75

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Munzone E, Nole F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT (2010) Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 10(5):392–397

    Article  CAS  PubMed  Google Scholar 

  51. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona S, Biganzoli L, Giannini A, Di Leo A (2009) Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 118(3):523–530

    Article  CAS  PubMed  Google Scholar 

  52. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K (2010) Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16(9):2634–2645

    Article  CAS  PubMed  Google Scholar 

  53. Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, Brandt B (2006) HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12(6):1715–1720

    Article  PubMed  Google Scholar 

  54. Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D (2007) Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 18(5):851–858

    Article  CAS  PubMed  Google Scholar 

  55. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT (2012) Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol 17(2):96–104

    Article  PubMed  Google Scholar 

  56. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A’Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69(7):2912–2918

    Google Scholar 

  57. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME (2010) Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 56(9):1492–1495

    Article  PubMed  Google Scholar 

  58. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M, Scher HI (2009) Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 15(6):2091–2097

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI (2007) Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13(7):2023–2029

    Article  CAS  PubMed  Google Scholar 

  60. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Hofler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR (2013) Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 73(10):2965–2975

    Article  CAS  PubMed  Google Scholar 

  61. Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z, Zong C, Bai H, Chapman AR, Zhao J, Xu L, An T, Ma Q, Wang Y, Wu M, Sun Y, Wang S, Li Z, Yang X, Yong J, Su XD, Lu Y, Bai F, Xie XS, Wang J (2013) Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A 110(52):21083–1088

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Swennenhuis JF, Reumers J, Thys K, Aerssens J, Terstappen LW (2013) Efficiency of whole genome amplification of single circulating tumor cells enriched by Cell Search and sorted by FACS. Genome Med 5(11):106

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  63. Ahn JY, Min HY, Jeong JH, Byun Y, Lee HY (2013) A preclinical murine model for the detection of circulating human tumor cells. Anticancer Res 33(11):4751–4756

    CAS  PubMed  Google Scholar 

  64. Eliane JP, Repollet M, Luker KE, Brown M, Rae JM, Dontu G, Schott AF, Wicha M, Doyle GV, Hayes DF, Luker GD (2008) Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. Cancer Res 68(14):5529–5532

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Ameri K, Luong R, Zhang H, Powell AA, Montgomery KD, Espinosa I, Bouley DM, Harris AL, Jeffrey SS (2010) Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer 102(3):561–569

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES, Georgoulias V, Mavroudis D, Agelaki S (2009) Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 11(6):R84

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  67. Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, Noel A, Foidart JM, Birembaut P, Polette M, Gilles C (2012) A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 31(33):3741–3753

    Article  CAS  PubMed  Google Scholar 

  68. Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, Chang TC, Weitman SD, Kumar AP, Sun L, Gaczynska ME, Thompson IM, Huang TH (2013) Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate 73(8):813–826

    Article  PubMed  CAS  Google Scholar 

  69. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM (2012) Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 11(11):2526–2534

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. He H, Yang X, Davidson AJ, Wu D, Marshall FF, Chung LW, Zhau HE, Wang R (2010) Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis. Prostate 70(5):518–528

    PubMed Central  CAS  PubMed  Google Scholar 

  71. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T (2012) Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 14(1):R15

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM (2012) Prognostic value of EMT-circulating tumor cells in metastatic breast cancer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation. J Cancer Educ 3:369–380

    Article  CAS  Google Scholar 

  73. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148(1-2):349–361

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Nadal R, Ortega FG, Salido M, Lorente JA, Rodriguez-Rivera M, Delgado-Rodriguez M, Macia M, Fernandez A, Corominas JM, Garcia-Puche JL, Sanchez-Rovira P, Sole F, Serrano MJ (2013) CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 133(10):2398–2407

    Article  CAS  PubMed  Google Scholar 

  75. Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL (2014) Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration resistant prostate cancer. Int J Cancer 134(10):2284–93

    Article  CAS  PubMed  Google Scholar 

  76. Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, Yang Z, Harvey HA, Cream LV, Kumar SM, Robertson GP, Zheng S, Drabick JJ, Truica CI, El-Deiry WS (2013) Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle 12(13):2132–2143

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, Goodman JC, Groves MD, Marchetti D (2013) The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 5(180):180ra148

    Article  CAS  Google Scholar 

  78. Goss PE, Chambers AF (2010) Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 10(12):871–877

    Article  CAS  PubMed  Google Scholar 

  79. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802

    Article  CAS  PubMed  Google Scholar 

  80. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97(17):1262–1271

    Article  CAS  PubMed  Google Scholar 

  81. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D (2008) Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26(12):1948–1955

    Article  CAS  PubMed  Google Scholar 

  82. Goss P, Allan AL, Rodenhiser DI, Foster PJ, Chambers AF (2008) New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? APMIS 116(7-8):552–568

    Article  CAS  PubMed  Google Scholar 

  83. Strasser-Weippl K, Badovinac-Crnjevic T, Fan L, Goss PE (2013) Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer. Breast 22(Suppl 2):S171–S175

    Article  PubMed  Google Scholar 

  84. Meltzer A (1990) Dormancy and breast cancer. J Surg Oncol 43(3):181–188

    Article  CAS  PubMed  Google Scholar 

  85. Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G (1997) Proposal for a new model of breast cancer metastatic development. Ann Oncol 8(11):1075–1080

    Article  CAS  PubMed  Google Scholar 

  86. Uhr JW, Pantel K (2011) Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 108(30):12396–12400

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  87. Townson JL, Chambers AF (2006) Dormancy of solitary metastatic cells. Cell Cycle 5(16):1744–1750

    Article  CAS  PubMed  Google Scholar 

  88. Kang Y, Pantel K (2013) Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 23(5):573–581

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  89. Hensel JA, Flaig TW, Theodorescu D (2013) Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol 10(1):41–51

    Article  CAS  PubMed  Google Scholar 

  90. Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, Wilson SM, Morris VL, Groom AC, Chambers AF (2002) Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 62(7):2162–2168

    CAS  PubMed  Google Scholar 

  91. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153(3):865–873

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  92. O’Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2(6):689–692

    Google Scholar 

  93. Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1(2):149–153

    Google Scholar 

  94. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, Chambers AF (2003) Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 82(3):199–206

    Article  CAS  PubMed  Google Scholar 

  95. Townson JL, Ramadan SS, Simedrea C, Rutt BK, MacDonald IC, Foster PJ, Chambers AF (2009) Three-dimensional imaging and quantification of both solitary cells and metastases in whole mouse liver by magnetic resonance imaging. Cancer Res 69(21):8326–8331

    Article  CAS  PubMed  Google Scholar 

  96. Townson JL, Macdonald IC, Liby KT, Mackenzie L, Dales DW, Hedley BD, Foster PJ, Sporn MB, Chambers AF (2011) The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. Clin Exp Metastasis 28(3):309–317

    Article  CAS  PubMed  Google Scholar 

  97. Marshall JC, Collins JW, Nakayama J, Horak CE, Liewehr DJ, Steinberg SM, Albaugh M, Vidal-Vanaclocha F, Palmieri D, Barbier M, Murone M, Steeg PS (2012) Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst 104(17):1306–1319

    PubMed Central  CAS  PubMed  Google Scholar 

  98. Marino N, Nakayama J, Collins JW, Steeg PS (2012) Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene. Cancer Metastasis Rev 31(3-4):593–603

    Article  CAS  PubMed  Google Scholar 

  99. Giancotti FG (2013) Mechanisms governing metastatic dormancy and reactivation. Cell 155(4):750–764

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  100. Barkan D, Green JE, Chambers AF (2010) Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 46(7):1181–1188

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  101. Nash KT, Phadke PA, Navenot JM, Hurst DR, Accavitti-Loper MA, Sztul E, Vaidya KS, Frost AR, Kappes JC, Peiper SC, Welch DR (2007) Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 99(4):309–321

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  102. Hedley BD, Chambers AF (2009) Tumor dormancy and metastasis. Adv Cancer Res 102:67–101

    Article  CAS  PubMed  Google Scholar 

  103. Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147(1):89–104

    Article  CAS  PubMed  Google Scholar 

  104. Ossowski L, Aguirre Ghiso J, Liu D, Yu W, Kovalski K (1999) The role of plasminogen activator receptor in cancer invasion and dormancy. Medicina (B Aires) 59(5 Pt 2):547–552

    CAS  Google Scholar 

  105. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7(11):834–846

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  106. Allgayer H, Aguirre-Ghiso JA (2008) The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS 116(7-8):602–614

    Google Scholar 

  107. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, Liu ZY, Costes SV, Cho EH, Lockett S, Khanna C, Chambers AF, Green JE (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68(15):6241–6250

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  108. Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4(4):359–365

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  109. Barkan D, Chambers AF (2011) β1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 17(23):7219–7223

    Article  CAS  PubMed  Google Scholar 

  110. Esposito M, Kang Y (2013) Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther 141(2):222–233

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  111. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY, Chen EI, Lyden D, Bissell MJ (2013) The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 15(7):807–817

    Article  CAS  PubMed  Google Scholar 

  112. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10(24):8152–8162

    Article  PubMed  Google Scholar 

  113. Jochelson M, Hayes DF, Ganz PA (2013) Surveillance and monitoring in breast cancer survivors: maximizing benefit and minimizing harm. Am Soc Clin Oncol Educ Book 13–18

    Google Scholar 

  114. Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8(6):378–382

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank our clinical oncology colleagues Drs. Vivien Bramwell, Nicholas Power, Ted Vandenberg, Eric Winquist, David Palma, and Robert Bristow for helpful discussion around CTCs and tumor dormancy. A.L.A is supported by a Canadian Institutes for Health Research (CIHR) New Investigator Award and an Early Researcher Award from the Ontario Ministry of Research and Innovation. A.F.C. is Canada Research Chair in Oncology.

Author information

Authors and Affiliations

  1. Departments of Oncology & Pathology, London Regional Cancer Program, University of Western Ontario, London, ON, Canada

    Alison L. Allan Ph.D.

  2. Departments of Oncology, Medical Biophysics and Pathology & Laboratory Medicine, London Regional Cancer Program, London Health Sciences Centre/University of Western Ontario, 790 Commissioners Road East, London, ON, N6A 4L6, Canada

    Ann F. Chambers Ph.D.

Authors
  1. Alison L. Allan Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann F. Chambers Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ann F. Chambers Ph.D. .

Editor information

Editors and Affiliations

  1. Jackson Memorial Hospital, University of Miami, Miami, Florida, USA

    Richard J. Cote

  2. University of Miami, Miami, Florida, USA

    Ram H. Datar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Allan, A.L., Chambers, A.F. (2016). Circulating Tumor Cells and Tumor Dormancy. In: Cote, R., Datar, R. (eds) Circulating Tumor Cells. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3363-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3363-1_6

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-3361-7

  • Online ISBN: 978-1-4939-3363-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation